1. Insulin-Like Growth Factor-1 Alleviates Expression of Aβ1–40 and α-, β-, and γ-Secretases in the Cortex and Hippocampus of APP/PS1 Double Transgenic Mice
- Author
-
Li-Hong Jiang, Tingting Liu, Fang-Fang Song, Songyan Meng, Fengqing Li, and Yina Zhang
- Subjects
0301 basic medicine ,Genetically modified mouse ,medicine.medical_specialty ,medicine.diagnostic_test ,Chemistry ,Transgene ,medicine.medical_treatment ,ADAM10 ,Hippocampus ,General Medicine ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Insulin-like growth factor ,Subcutaneous injection ,030104 developmental biology ,0302 clinical medicine ,Endocrinology ,medicine.anatomical_structure ,Western blot ,Internal medicine ,Cortex (anatomy) ,mental disorders ,medicine ,030217 neurology & neurosurgery - Abstract
To examine the effect of subcutaneous injection of insulin-like growth factor-1 (IGF-1) on the expression of the amyloid protein (Aβ1–40), α-secretase (ADAM10), β-secretase (BACE1), and γ-secretase (PS1) in APP/PS1 double transgenic mice. APP/PS1 double transgenic mice and wild-type mice were divided into wild-type group, wild-type therapy group, transgenome group, and transgenic therapy group. Subcutaneous injection of IGF-1 (50 μg/kg day) was administered once daily to the wild-type therapy group and transgenic therapy group for 8 weeks, respectively. The expression of the Aβ1–40 in the cortex and hippocampus was detected by immunohistochemistry 8 weeks after administration. The levels of Aβ1–40, DAM10, BACE1, and PS1 were analysed by Western blot. The expression of the Aβ1–40 in the cortex of the gene therapy group was significantly lower than that of the transgenome group (p
- Published
- 2018